Holen Sie sich die Stockscreener-App
2.52
0.80%
0.02
Handel nachbörslich:
2.52
Schlusskurs vom Vortag:
$2.50
Offen:
$2.47
24-Stunden-Volumen:
455.71K
Relative Volume:
0.52
Marktkapitalisierung:
$227.47M
Einnahmen:
$70.14M
Nettoeinkommen (Verlust:
$-76.24M
KGV:
-2.2703
EPS:
-1.11
Netto-Cashflow:
$-57.06M
1W Leistung:
-1.56%
1M Leistung:
+3.70%
6M Leistung:
+9.57%
1J Leistung:
-21.74%
1-Tages-Spanne:
$2.46
$2.55
1-Wochen-Bereich:
$2.455
$2.9299
52-Wochen-Spanne:
$1.90
$6.08
Codexis Inc Stock (CDXS) Company Profile
Firmenname
Codexis Inc
Sektor
Branche
Telefon
650-421-8100
Adresse
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Vergleichen Sie CDXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.52 | 225.67M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-19 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-29 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-07 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-08-07 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2021-04-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-01 | Eingeleitet | Stifel | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-10 | Eingeleitet | The Benchmark Company | Buy |
| 2019-01-17 | Hochstufung | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | Eingeleitet | Stephens | Overweight |
| 2017-10-13 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-31 | Eingeleitet | Jefferies | Buy |
| 2017-01-26 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Codexis Inc Aktie (CDXS) Neueste Nachrichten
How hedge fund analytics apply to Codexis Inc. stockWeekly Trade Analysis & Scalable Portfolio Growth Ideas - newser.com
Will Codexis Inc. price bounce be sustainableEarnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
Technical signs of recovery in Codexis Inc.2025 EndofYear Setup & Trade Opportunity Analysis Reports - newser.com
Long term hold vs stop loss in Codexis Inc.Earnings Overview Report & Consistent Return Strategy Ideas - newser.com
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Detecting price anomalies in Codexis Inc. with AIEarnings Recap Summary & Short-Term Swing Trade Alerts - newser.com
CDXSCodexis Reports First Quarter 2025 Financial Results - ADVFN
What institutional flow reveals about Codexis Inc.Weekly Trade Recap & Community Verified Trade Signals - newser.com
Will Codexis Inc. bounce back from current support2025 Major Catalysts & Long Hold Capital Preservation Plans - newser.com
Will Codexis Inc. continue its uptrend2025 Risk Factors & High Win Rate Trade Alerts - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Codexis (NASDAQ:CDXS) - MarketBeat
Is Codexis Inc a good long term investmentHead and Shoulders Patterns & Demo Trading Rooms Open Daily - earlytimes.in
Codexis Inc Stock Analysis and ForecastPortfolio Risk Assessment & Build a Dividend-Powered Portfolio - earlytimes.in
Biocatalysis And Biocatalyst Market Rewriting Long Term Growth Story| Codexis, Amano Enzyme, Biocatalysts - openPR.com
Codexis (NASDAQ:CDXS) Stock Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Codexis Inc. stock retracement – recovery analysisJuly 2025 Pullbacks & Safe Capital Growth Stock Tips - newser.com
What does recent volatility data suggest for Codexis Inc.July 2025 Action & Daily Growth Stock Investment Tips - newser.com
Will Codexis Inc. stock recover after recent dropWeekly Trend Summary & Weekly Top Gainers Alerts - newser.com
News impact scoring models applied to Codexis Inc.Portfolio Growth Summary & Advanced Swing Trade Entry Alerts - newser.com
What analysts say about Codexis Inc stockRisk-Reward Ratio Analysis & Exceptional Profit Trading - earlytimes.in
Assenagon Asset Management S.A. Sells 372,591 Shares of Codexis, Inc. $CDXS - MarketBeat
Rhumbline Advisers Sells 7,421 Shares of Codexis, Inc. $CDXS - Defense World
Investors in Codexis (NASDAQ:CDXS) have unfortunately lost 79% over the last five years - Yahoo Finance
Codexis, Inc. $CDXS Shares Sold by Goldman Sachs Group Inc. - Defense World
Strs Ohio Buys New Position in Codexis, Inc. $CDXS - Defense World
Real time scanner hits for Codexis Inc. explainedGlobal Markets & Risk Controlled Daily Plans - newser.com
Applying sector rotation models to Codexis Inc.2025 Fundamental Recap & Verified Short-Term Plans - newser.com
Finanzdaten der Codexis Inc-Aktie (CDXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):